Quick Take
Centogene (OTC:CNTG) has filed to raise $60 million from the sale of common stock in a U.S. IPO, according to an amended F-1/A registration statement.
The company provides genetic insights to researchers and clinicians in various regions worldwide.
CNTG is producing accelerating topline revenue growth, but decelerating gross profit growth and increased operating losses, indicating no path to profitability any time soon.
I'm passing on this IPO.
Company & Technology
Rostock, Germany-based Centogene was founded in 2006 and has developed a rare diseases platform with over 2 billion weighted data